Eversana, Canada
Disclosure information not submitted.
Developing a de-novo mortality model for relapsed and refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data
Tuesday, August 27, 20241:15 PM – 1:30 PM CEST
